StemBioSys launches CELLvo™ Human Articular Chondrocytes, low passage cells for highly relevant cartilage research

Freshly isolated human chondrocytes exhibit a natural, biologically relevant phenotype during in vitro expansion

SAN ANTONIO, TX, April 14, 2020 – Investigators exploring chondrocytes in vitro have the ability to study a more biologically-relevant phenotype with CELLvo™ Human Articular Chondrocytes from StemBioSys. Isolated from healthy donors, CELLvo™ Chondrocytes are available to scientists before being cultured at passage 0, or upon a single passage and expansion on CELLvo™ Matrix, the company’s novel growth substrate. When cultured on CELLvo™ Matrix, CELLvo™ Chondrocytes home, attach and proliferate more rapidly, and exhibit similar morphology to in vivo chondrocytes. CELLvo™ Chondrocytes are shown to minimize loss of phenotype during in vitro expansion on CELLvo™ Matrix through the expression of a high ratio of type 2 collagen (Col2) to type 1 collagen (Col1), a significant marker for determining chondrogenic potential. StemBioSys CELLvo™ Human Chondrocytes never come in contact with non-human proteins or plastic thereby offering a streamlined pathway to clinical studies. The CELLvo™ Human Chondrocyte cell culture system offers exceptional promise to basic and translational studies of osteoarthritis, joint function, chondrocyte differentiation, tissue engineering and chondrocyte implantation. 

“Research with human primary cells saves time in bringing discoveries from the bench to the clinic,” says Bob Hutchens, StemBioSys President and CEO. “Our innovative approach involves creating a micro-environment for human cells, so we expanded the CELLvo™ platform from extracellular matrices to primary cells,” he added.
CELLvo™ Human Chondrocytes are shipped in vials containing >1,000,000 cryopreserved cells; scientists may request cells at P1 or P0. CELLvo™ Human Chondrocytes (P1) have been isolated and expanded on CELLvo™ Matrix. CELLvo™ Human Chondrocytes (P0) have never been cultured; as with any freshly isolated cells, it may take a longer period of time for cells to attach compared to previously passaged cells. It is not unusual for viable cells to be floating after several days in culture. This is to be expected.  StemBioSys scientists are ready to assist if needed.
CELLvo™ Human Chondrocytes are not intended for diagnostic or therapeutic purposes. For more information, visit the website at or call +1 (210) 877-9323. StemBioSys products are available from leading laboratory supply distributors.
About StemBioSys
StemBioSys, Inc., a privately held, San Antonio-based biomedical company, manufactures and develops innovative, advanced cell culture technologies to meet the promise of regenerative medicine in a surging global market. Its patented and proprietary technology platforms – licensed from the University of Texas System – overcome key obstacles to creating clinically useful cell therapies. StemBioSys markets its products to the global research community under the CELLvo™ brand name. 

Share this article

More services


This article is featured in:
Pharmacology/ Therapeutics


Comment on this article

You must be registered and logged in to leave a comment about this article.